| scholarly article | Q13442814 |
| P356 | DOI | 10.4049/JIMMUNOL.165.9.4917 |
| P698 | PubMed publication ID | 11046017 |
| P50 | author | Maria Leite-De-Moraes | Q68295385 |
| P2093 | author name string | Y Koezuka | |
| J F Bach | |||
| C Garcia | |||
| A Herbelin | |||
| J M Gombert | |||
| A Hameg | |||
| I Apostolou | |||
| P433 | issue | 9 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 4917-4926 | |
| P577 | publication date | 2000-11-01 | |
| P1433 | published in | Journal of Immunology | Q3521441 |
| P1476 | title | A subset of NKT cells that lacks the NK1.1 marker, expresses CD1d molecules, and autopresents the alpha-galactosylceramide antigen | |
| P478 | volume | 165 |
| Q36370202 | A natural killer T (NKT) cell developmental pathway iInvolving a thymus-dependent NK1.1(-)CD4(+) CD1d-dependent precursor stage |
| Q74455329 | Activation of natural killer T cells by alpha-galactosylceramide treatment prevents the onset and recurrence of autoimmune Type 1 diabetes |
| Q37628580 | B cells interactions in lipid immune responses: implications in atherosclerotic disease |
| Q79957812 | Freshly isolated Valpha24+ CD4+ invariant natural killer T cells activated by alpha-galactosylceramide-pulsed B cells promote both IgG and IgE production |
| Q34807830 | IL-15 availability conditions homeostasis of peripheral natural killer T cells |
| Q37405955 | Intracellular bacterial infection and invariant NKT cells |
| Q34985362 | Invariant NKT Cell Lines Derived from the NOD·H2 Mouse Enhance Autoimmune Thyroiditis. |
| Q36746282 | Invariant NKT cells are resistant to circulating CD15+ myeloid-derived suppressor cells in patients with head and neck cancer. |
| Q45216367 | Involvement of high mobility group box 1 and the therapeutic effect of recombinant thrombomodulin in a mouse model of severe acute respiratory distress syndrome. |
| Q47895830 | NKT cells: what's in a name? |
| Q35073920 | Rapid development of a gamma interferon-secreting glycolipid/CD1d-specific Valpha14+ NK1.1- T-cell subset after bacterial infection |
| Q54643220 | Suppression of eosinophilic airway inflammation by treatment with alpha-galactosylceramide. |
| Q41613542 | Type I interferon contributes to noncanonical inflammasome activation, mediates immunopathology, and impairs protective immunity during fatal infection with lipopolysaccharide-negative ehrlichiae |
Search more.